Exercise was part of the trials, not a substitute for the drug
Every pivotal GLP-1 obesity trial gave the medication on top of a lifestyle program, not instead of one. In STEP 1, all 1,961 participants received a reduced-calorie diet and activity counseling alongside semaglutide 2.4 mg or placebo (New England Journal of Medicine, 2021). The results that make headlines, roughly 15% average weight loss, come from that drug-plus-lifestyle combination, not the drug in isolation.
This matters for expectations. GLP-1 medications work largely by reducing appetite and food intake, which drives the calorie deficit. Exercise contributes something the drug does not: it stimulates muscle, supports cardiorespiratory fitness, and helps protect the quality of the weight you lose. Framing activity as a tool that makes the medication work better, rather than an add-on chore, is how clinicians increasingly describe the pairing (Endocrinology Advisor, 2026).
Nothing here tells you to start, stop, or change any exercise or medication. Whether and how you should exercise depends on your health, fitness, and other conditions, which is a conversation for your clinician.
Why muscle (lean mass) is the thing exercise protects
The central reason exercise matters on a GLP-1 is lean-mass loss. When you lose weight quickly, you lose both fat and fat-free mass, which includes skeletal muscle. Across anti-obesity medications, lean mass has accounted for about 20% to 50% of total weight lost (Current Developments in Nutrition, 2024). A clinical review put the STEP 1 (semaglutide) and SURMOUNT (tirzepatide) figures at roughly 30-40% of lost weight being lean body mass (Endocrinology Advisor, 2026).
The numbers from STEP 1's DEXA body-composition substudy make this concrete. Over 68 weeks, semaglutide 2.4 mg reduced total body weight by 15.0%. Total fat mass fell 19.3% and visceral fat 27.4%, but total lean body mass also dropped 9.7% from baseline. Importantly, because fat fell faster, lean mass rose as a proportion of body weight, from about 53.9% to 57.4% (Journal of the Endocrine Society, 2021). So body composition improved on average, even as absolute muscle declined.
A group of obesity-medicine experts framed the scale of absolute muscle loss bluntly: trial participants lost 10% or more of their muscle mass over the 68- to 72-week studies, an amount they compared to roughly 20 years of age-related muscle loss (Mechanick et al., 2024). That is the loss resistance training and protein aim to blunt.
Resistance training plus protein: the best-studied way to preserve muscle
If there is one evidence-based headline, it is this: structured resistance (strength) training combined with adequate protein is the best-established way to preserve muscle during weight loss, and higher protein alone, without strength training, is likely not enough. That is the explicit conclusion of a 2025 joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (American Journal of Clinical Nutrition, 2025).
That Advisory suggests, for people on GLP-1s, aiming for strength training at least 3 times weekly plus at least 150 minutes of moderate-intensity aerobic activity per week, matched to the individual's fitness level. Systematic reviews it cites found resistance training effective for maintaining muscle mass during calorie restriction, while aerobic activity alone had a smaller muscle-preserving effect.
On protein, the Advisory notes the general adult RDA is 0.8 g/kg/day, with higher targets of about 1.2-1.6 g/kg/day proposed during active weight loss; it flags that intake should not fall below roughly 0.4-0.5 g/kg/day and that sustained intake at or above 2 g/kg/day should be avoided. An absolute target of about 80-120 g/day is offered as a practical alternative. These are population reference ranges, not a prescription. Because appetite suppression can make it hard to eat enough protein, small frequent meals, smoothies, and protein-containing drinks are common practical suggestions, ideally guided by a registered dietitian.
What happens when you combine a GLP-1 with exercise: the S-LITE trial
The clearest head-to-head evidence comes from the S-LITE trial (Lundgren et al., New England Journal of Medicine, 2021). After an 8-week low-calorie diet that produced about 13.1 kg of weight loss, 195 adults with obesity were randomized for one year to one of four strategies: supervised exercise plus placebo, liraglutide 3.0 mg (a daily GLP-1) plus usual activity, exercise plus liraglutide, or placebo.
Compared with placebo, weight loss over the year was 4.1 kg greater with exercise alone, 6.8 kg greater with liraglutide alone, and 9.5 kg greater with the combination. The combination cut body-fat percentage by 3.9 points, roughly double the reduction from either strategy alone. Crucially for muscle, exercise alone increased lean mass, and the combination preserved lean mass, whereas the drug-alone group did not get that protection. Only the combination improved HbA1c, insulin sensitivity, and cardiorespiratory fitness.
A follow-up analysis a year after everyone stopped treatment found the exercise group had regained the least weight, and the former combination group maintained its loss better than the liraglutide-alone group (eClinicalMedicine, 2024). The takeaway researchers drew is that building an exercise habit during treatment may pay off for long-term maintenance, though S-LITE tested liraglutide specifically, and this is background evidence, not individualized advice.
Lower energy and appetite around workouts
A practical challenge on GLP-1s is that reduced appetite and, sometimes, lower energy can make workouts feel harder or make it easy to under-fuel. Because these medications blunt hunger, some people simply forget to eat before exercising, which can leave them light-headed or flat during a session.
General, non-prescriptive strategies people and clinicians discuss include a small protein-containing snack before activity, keeping sessions manageable especially early in treatment or during dose changes, and prioritizing consistency over intensity. One clinical review noted the practical idea of a high-protein snack roughly 30 minutes before exercise and paying attention to how you feel during dose titration or when starting a new routine (Endocrinology Advisor, 2026).
There is also a blood-sugar caution: exercise independently lowers blood glucose, and hypoglycemia is a particular concern for people also taking insulin or insulin secretagogues (sulfonylureas). Symptoms can include shakiness, dizziness, sweating, or confusion. If this applies to you, do not self-manage it from a web page; ask the clinician who prescribes your medications how to handle activity, fueling, and any glucose monitoring.
Hydration and GI side effects during exercise
GLP-1 medications commonly cause gastrointestinal side effects, most often nausea, and sometimes vomiting, diarrhea, or constipation, especially early on and around dose increases. Vomiting and diarrhea can cause fluid loss, and exercise adds sweat losses on top, so staying adequately hydrated is a reasonable, commonsense priority. Managing GI symptoms is described as a critical part of GLP-1 care in the 2025 multi-society Advisory (American Journal of Clinical Nutrition, 2025).
Practically, that can mean drinking fluids across the day rather than all at once, being cautious with intense exercise on a day when nausea is high, and not forcing a workout through significant GI distress. Some people find lighter or lower-impact activity more tolerable when their stomach is unsettled.
These are general observations, not a treatment plan. Persistent vomiting, signs of dehydration, or severe abdominal pain are reasons to contact a clinician rather than to push through a workout. Nothing here should be read as telling you to change your dose or your fluid intake for a medical condition.
General guidance, not a training plan
This page deliberately does not prescribe a specific workout program, number of sets, or exercise schedule for you, because the right plan depends on your age, fitness, joint and heart health, other conditions, and medications. Published guidance stresses that activity programs should be individualized and, where possible, developed with help from a clinician, exercise physiologist, physical therapist, or registered dietitian (American Journal of Clinical Nutrition, 2025; Mechanick et al., 2024).
The reference table below summarizes what evidence and current guidance describe at a population level. Treat it as context for a conversation with your care team, not as instructions. The Physical Activity Guidelines for Americans similarly describe at least 150-300 minutes of moderate-intensity aerobic activity per week plus muscle-strengthening activity on two or more days as a general adult target.
Bottom line: the drug and the workout are teammates. The medication drives appetite down and weight loss up; resistance training and protein help make sure more of what you lose is fat and less is muscle. How to apply that to your body is a clinician's call.